

- Endometritis (*Cont.*):
 anaerobic bacterial, 1099
C. trachomatis, 1169
 clinical features of, 338
 clostridial, 991t, 994
 etiology of, 338
- Endomyocardial biopsy, 1559, 1560f
- Endomyocardial fibrosis, 1567–1568
- Endomyometritis, postpartum, 50
- Endophthalmitis
Candida, 1343, 1343f, 1345
 clinical features of, 200, 201f
 etiology of, 200
Nocardia, 1086
P. aeruginosa, 1045t, 1046
- β-Endorphin, 386
- Endoscopic retrograde
 cholangiopancreatography (ERCP)
 in acute biliary obstruction, 1892
 in bile duct evaluation, 2085t
 in bile duct leak, 1885f
 in bile duct stones, 1884f, 1892
 in cholangiocarcinoma, 552–553, 1885f
 in cholestasis, 283–284
 in gallstone pancreatitis, 1893–1894
 indications for, 1878, 1879t, 1881
 in liver disease, 1993
 in pancreatic cancer, 555, 555f, 1894f
 in pancreatic disease, 2089
 in pancreatitis, 2095f
 pancreatitis after, 2091
 in primary sclerosing cholangitis, 1958, 2061
 procedure, 1881
 risks of, 1884
- Endoscopic secretin test, 2087t
- Endoscopic sphincterotomy, 346e-1f, 1881, 1884f
- Endoscopic therapy. *See also* Gastrointestinal endoscopy
 for achalasia, 1905
 for chronic pancreatitis, 2101
 for colonic pseudoobstruction, 1894f
 for esophageal varices, 277, 1890–1891, 1890f, 2063–2064, 2064f
 for gastric outlet obstruction, 1893f, 1894f
 for gastrointestinal bleeding, 277, 278f, 1890f
 for gastrointestinal malignancies, 346e-1v, 1885f, 1886f, 1887f, 1896
 for ileal stricture, 1884f
 indications for, 1880
 for intestinal obstruction, 1895f
 for Mallory-Weiss tears, 277
 mucosal dissection, 346e-1v, 1883–1884
 natural orifice transluminal endoscopic (NOTES) surgery, 346e-1v, 1881, 1883, 1886f
 for peptic ulcer disease, 277, 1890f
 sphincterotomy, 1884f
 submucosal dissection, 346e-1v, 1883–1884, 1887f, 1896
 suturing, 346e-1v, 1884, 1887f, 1888f
 for vascular ectasia, 1897, 1897f
- Endoscopic ultrasound (EUS)
 of bile duct, 1892, 1895f
 in bile duct evaluation, 2085t
 in chronic pancreatitis, 2100
 in esophageal disease, 1901
 with fine-needle aspiration, 1881, 1886f, 1900
 for gastrointestinal cancer staging, 1878, 1881, 1885f
 indications for, 1878, 1879t, 1881
 in pancreatic cancer, 554, 555
 in pancreatic disease evaluation, 2087t, 2089, 2089t
 for pancreatic necrosis, 346e-1v
 in pNETs, 572
- Endoscopy. *See* Gastrointestinal endoscopy
- Endosomes, 373e-5
- Endospores, 1335, 1335f
- Endostatin, 102e-17f
- Endothelial lipase, 2438
- Endothelial nitric oxide synthase (eNOS)
 in bicuspid aortic valve disease, 1529
 in brush cells, 213
 in cirrhosis, 286
 in female sexual response, 330
 in vascular function, 291e-2
- Endothelin(s)
 in cardiovascular function, 265e-2, 265e-4
 in edema, 251
 in male sexual function, 324, 325f
 in shock, 1745
 in thyroid function, 2285
- Endothelin receptor antagonists, 1615, 1659–1660, 1660t
- Endothelium
 antithrombotic effects of, 402
 biology of, 265e-1–2
 clinical assessment of, 265e-2f
 functions of, 265e-1–2, 265e-2t
 injury in sepsis/septic shock, 1754
 lymphocyte interactions with, 372e-26–28, 372e-29t
 in modulation of vascular tone, 1615
 in tumor angiogenesis, 102e-14–15, 102e-14f, 102e-15f, 102e-16f
- Endothelium-derived hyperpolarizing factor, 265e-1, 265e-4
- Endotoxin, 145e-9, 1752
- Endotoxin challenge test, 423
- Endotracheal intubation. *See also* Mechanical ventilation
 in cardiac arrest, 1769
 clinical procedure tutorial, 484e-1v
 for hemoptysis, 247
- Endotracheal suctioning, 810, 1467, 1467t
- Endovascular procedures. *See* Percutaneous interventions
- End-stage renal disease (ESRD). *See* Chronic kidney disease (CKD), stage 5
- End-systolic left ventricular pressure-volume relationship, 265e-10, 265e-10f
- Enema
 barium. *See* Barium radiography
 for constipation, 61, 62t
- Energy balance, 95e-1
 in aging, 73, 74f, 75
 assessment of, 73t
 physiologic regulation of, 415e-2, 415e-2f
- Energy density, of food, 2395
- Energy expenditure, 95e-1, 415e-2, 415e-5
- Energy requirements, 95e-1, 98e-4–5, 461, 462–463
- Enfuvirtide
 action of, 214e-3, 214e-9, 1281
 adverse effects of, 1275t, 1281
 for HIV infection, 214e-9, 1275t, 1281
 molecular structure of, 1277f
 resistance to, 1280f, 1281
- Enhanced external counterpulsation, 1513, 1592
- Enolase, 947f
- β-Enolase deficiency, 433e-2t, 462e-14
- Enophthalmos, 207
- eNOS. *See* Endothelial nitric oxide synthase (eNOS)
- Enoxaparin
 discontinuation before lumbar puncture, 443e-1
 for myocardial infarction, 1597, 1598t
 in PCI, 296e-1
 for VTE prophylaxis, 1637t
 for VTE treatment, 1635t
- Entacapone, 2615, 2616t
- Entamoeba dispar*, 1363
- Entamoeba histolytica*. *See also* Amebiasis
 adherence of, 145e-2t, 145e-3
 entry into host, 145e-8
 epidemiology of, 245e-4t
 immune response to, 1365
 laboratory identification of, 245e-1, 245e-3, 245e-4t, 245e-5t, 245e-6, 1365–1366
 life-cycle hosts of, 245e-4t
 life cycle of, 1363, 1364f
 phagocyte interaction with, 145e-7
 tissue invasion by, 145e-8, 1364, 1364f
 virulence factors of, 1364
- Entamoeba moshkovskii*, 1363
- Entecavir
 action of, 215e-9
 for chronic HBV infection, 215e-4t, 215e-10, 2036, 2037t, 2038f
 for HBV prophylaxis in transplant recipient, 927
 pharmacology of, 215e-9
 resistance to, 215e-10, 2040t
- Enteral feeding tubes, 98e-8, 98e-8t
- Enteral nutrition, **98e-1**. *See also* Specialized nutritional support
 combined with parenteral feeding, 98e-3
 complications of, 98e-8–9
 definition of, 98e-1
 disadvantages of, 98e-1, 98e-3
 in esophageal cancer, 533
 formulas for, 98e-8t
 for IBD, 1962
 indications for, 98e-3
 patient monitoring in, 98e-8
 for sepsis/septic shock, 1757
 tube placement for, 98e-1, 98e-8
- Enteric (typhoid) fever
 vs. *Brucella* infection, 194e-2
 clinical features of, 129t, 853, 1050–1051, 1051f
 diagnosis of, 1051
 epidemiology of, 134, 1050, 1050f
 etiology of, 1050
 global considerations in, 1050, 1050f, 1052
 multidrug-resistant, 1050, 1052, 1052t
 pathogenesis of, 853, 1049
 prevention and control of, 1052–1053
 resistance to, 145e-3
 skin manifestations of, 25e-3f, 362, 362t, 1051f
 treatment of, 1052, 1052t
- Enteric hyperoxaluria, 1943
- Enteric nervous system, 264
- Enteritis
 drug-induced, 1940t
 radiation, 103e-4, 1940t
 sexually acquired, 881
- Enteritis necroticans, 991
- Enterogaggressive *E. coli* (EAEC), 1028t, 1031
- Enterobacter* spp., 1034
- Enterobacter* spp. infections, **1034**
 antibiotic resistance in, 807, 933, 1027, 1034
 in cancer patient, 486t
 clinical features of, 1034
 diagnosis of, 1034
 endocarditis, 823
 epidemiology of, 1025
 health care-associated pneumonia, 803t
 osteomyelitis, 840t, 841t
 risk factors for, 805
 sepsis and septic shock, 1752
 sinusitis, 226
 treatment of, 1034
 ventilator-associated pneumonia, 915
- Enterobius vermicularis*/enterobiasis (pinworm), 245e-3t, 245e-5t, 1414t, 1416
- Enterocoele, 274
- Enterococcal infections, **971**
 bacteremia, 973, 975t
 bone and joint, 974
 in cancer patient, 486t
 endocarditis, 817t, 821–823, 822t, 973–974, 975t
 epidemiology of, 973
 etiology of, 971–972, 972f
 global considerations in, 973
 health care-associated, 973
 intraabdominal, 974
 meningitis. *See* Meningitis, bacterial
 neonatal, 974
 osteomyelitis, 841t
 pathogenesis of, 972–973
 soft tissue, 974
 in transplant recipient, 923, 927
 treatment of, 974–976, 975t
 urinary tract, 862, 973, 975t
 vancomycin-resistant. *See* Vancomycin-resistant enterococci (VRE)